Immunotherapy for viral and fungal infections

Bone Marrow Transplantation

Volumn 50, Issue , 2015, Pages S51-S54

  Einsele, H ^a   Loffler J ^a   Kapp, M ^a   Rasche, L ^a   Mielke, S ^a   Grigoleit, U G ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BRINCIDOFOVIR; LETERMOVIR; THYMOCYTE ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CYTOMEGALOVIRUS INFECTION; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTIOUS COMPLICATION; INVASIVE ASPERGILLOSIS; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT FAILURE; TUMOR CELL; VIRUS INFECTION; ALLOGRAFT; HEMATOLOGIC NEOPLASMS; IMMUNOTHERAPY; MYCOSES; PROCEDURES; STEM CELL TRANSPLANTATION; VIRUS DISEASES;

ALLOGRAFTS; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY; MYCOSES; STEM CELL TRANSPLANTATION; VIRUS DISEASES;

EID: 84930442551     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2015.96     Document Type: Article

References (44)

1. Seggewiss R, Einsele H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010; 115: 3861-3868.
2. Einsele H, Hebart H, Kauffmann-Schneider C, Sinzger C, Jahn G, Bader P et al. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection. Bone Marrow Transplant 2000; 25: 757-763.
3. Marty FM, Winston DJ, Rowley SD, Vance E, Papanicolaou GA, Mullane KM et al. CMX001-201 Clinical Study Group. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 2013; 369: 1227-1236.
4. Rasche L, Kapp M, Einsele H, Mielke S. EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT. Bone Marrow Transplant 2014; 49: 163-167.
5. Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebocontrolled, randomised trial. Lancet. 2011Infect Dis 11: 284-292.
6. Feuchtinger T, Lücke J, Hamprecht K, Richard C, Handgretinger R, Schumm M et al. Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2005; 128: 503-509.
7. Gerdemann U, Vera JF, Rooney CM, Leen AM. Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant. J Vis Exp 2011; 51: 2736-2742.
8. Zandvliet ML, van Liempt E, Jedema I, Kruithof S, Kester MG, Guchelaar HJ et al. Simultaneous isolation of CD8(+) and CD4(+) T cells specific for multiple viruses for broad antiviral immune reconstitution after allogeneic stem cell transplantation. J Immunother 2011; 34: 307-319.
9. Stühler C, Khanna N, Bozza S, Zelante T, Moretti S, Kruhm M et al. Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans. Blood 2011; 117: 5881-5891.
10. Khanna N, Stühler C, Conrad B, Lurati S, Krappmann S, Einsele H et al. Generation of a multiple pathogen-specific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154. Blood 2011; 118: 1121-1131.
11. Hebart H, Bollinger C, Fisch P, Sarfati J, Meisner C, Baur M et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematologic malignancies. Blood 2002; 100: 4521-4528.
12. Perruccio K, Tosti A, Burchielli E, Topini F, Ruggeri L, Carotti A et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005; 106: 4397-4406.
13. Bouzani M, Ok M, McCormick A, Ebel F, Kurzai O, Morton CO et al. Human NK cells display important antifungal activity against Aspergillus fumigatus, which is directly mediated by IFN-release. J Immunol. 2011; 187: 1369-1376.
14. Bouzani M, Einsele H, Loeffler J. Functional analysis is a paramount prerequisite for understanding the in vitro interaction of human natural killer cells with Aspergillus fumigatus. J Infect Dis 2012; 205: 1025-1026.
15. Lehrnbecher T, Tramsen L, Koehl U, Schmidt S, Bochennek K, Klingebiel T. Immunotherapy against invasive fungal diseases in stem cell transplant recipients. Immunol Invest 2011; 40: 839-852.
16. Smetak M, Kimmel B, Birkmann J, Schaefer-Eckart K, Einsele H, Wilhelm M et al. Clinical-scale single-step CD4(+) and CD8(+) cell depletion for donor innate lymphocyte infusion (DILI). Bone Marrow Transplant 2008; 41: 643-650.
17. Wilhelm M, Smetak M, Schaefer-Eckart K, Kimmel B, Birkmann J, Einsele H et al. Successful adoptive transfer and in vivo expansion of haploidentical T cells. J Transl Med 2014; 12: 45.
18. Kunzmann V, Kimmel B, Herrmann T, Einsele H, Wilhelm M. Inhibition of phosphoantigen-mediated gammadelta T-cell proliferation by CD4+ CD25+ FoxP3+ regulatory T cells. Immunology 2009; 126: 256-267.
19. Kunzmann V, Bauer E, Wilhelm M. Gamma/delta T-cell stimulation by pamidronate. N Engl J Med. 1999; 340: 737-738.
20. Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 2000; 96: 384-392.
21. Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Löffler J et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99: 3916-3922.
22. Feuchtinger T, Matthes-Martin S, Richard C, Lion T, Fuhrer M, Hamprecht K et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006; 134: 64-76.
23. Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006; 12: 1160-1166.
24. Icheva V, Kayser S, Wolff D, Tuve S, Kyzirakos C, Bethge W et al. Adoptive transfer of EBNA1-specific T cells as a treatment of Epstein-Barr-Virus reactivation and lymphoproliferative disorders following allogeneic stem cell transplantation. J Clin Oncol 2013; 31: 39-48.
25. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011; 17: 1290-1297.
26. Stemberger C, Huster KM, Koffler M, Anderl F, Schiemann M, Wagner H et al. A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets. Immunity 2007; 27: 985-997.
27. Buchholz VR, Flossdorf M, Hensel I, Kretschmer L, Weissbrich B, Graf P et al. Disparate individual fates compose robust CD8+ T cell immunity. Science 2013; 340: 630-635.
28. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1991; 257: 238-241.
29. Schmitt A, Tonn T, Busch DH, Grigoleit GU, Einsele H, Odendahl M et al. Adoptive transfer and selective reconstitution of streptamer-selected cytomegalovirusspecific CD8+ T cells leads to virus clearance in patients after allogeneic peripheral blood stem cell transplantation. Transfusion 2011; 51: 591-599.
30. Rauser G, Einsele H, Sinzger C, Wernet D, Kuntz G, Assenmacher M et al. Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 2004; 103: 3565-3572.
31. Feuchtinger T, Opherk K, Bethge WA, Topp MS, Schuster FR, Weissinger EM et al. Adoptive transfer of pp-65 specific T-cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010; 116: 4360-4367.
32. Mielke S, McIver ZA, Shenoy A, Fellowes V, Khuu H, Stroncek DF et al. Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies. Biol Blood Marrow Transplant 2011; 17: 1855-1861.
33. Stühler C, Mielke S, Chatterjee M, Duell J, Lurati S, Rueckert F et al. Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease. Blood 2009; 114: 2829-2836.
34. Mielke S, Nunes R, Rezvani K, Fellowes VS, Venne A, Solomon SR et al. A clinicalscale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigenpresenting cells and a TH9402-based photodepletion technique. Blood 2008; 111: 4392-4402.
35. Mielke S, Rezvani K, Savani BN, Nunes R, Yong AS, Schindler J et al. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood 2007; 110: 1689-1697.
36. Mielke S, Solomon SR, Barrett AJ. Selective depletion strategies in allogeneic stem cell transplantation. Cytotherapy 2005; 7: 109-115 Review.
37. Feuchtinger T, Richard C, Joachim S, Scheible MH, Schumm M, Hamprecht K et al. Clinical grade generation of hexon-specific T cells for adoptive T-cell Transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother 2008; 31: 199-206.
38. Schottker B, Feuchtinger T, Schumm M, Klinker E, Handgretinger R, Einsele H et al. Five donors-one recipient: modeling a mosaic of granulocytes, natural killer and T cells from cord-blood and third-party donors. Nat Clin Pract Oncol 2008; 5: 291-295.
39. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013; 121: 5113-5123.
40. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995; 333: 1038-1044.
41. Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 2011; 118: 6050-6056.
42. Gerdemann U, Keirnan JM, Katari UL, Yanagisawa R, Christin AS, Huye LE et al. Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections. Mol Ther 2012; 20: 1622-1632.
43. Stemberger C, Graef P, Odendahl M, Albrecht J, Dössinger G, Anderl F et al. Lowest numbers of primary CD8+ T cells can reconstitute protective immunity upon adoptive immunotherapy. Blood 2014; 124: 628-637.
44. Jedema I, van de Meent M, Pots J, Kester MG, van der Beek MT, Falkenburg JH. Successful generation of primary virus-specific and anti-tumor T-cell responses from the naive donor T-cell repertoire is determined by the balance between antigen-specific precursor T cells and regulatory T cells. Haematologica 2011; 96: 1204-1212.